Evidence map›Paper›PMID 33123262›Full record

ArticleOncology letters2020

Novel canine isocitrate dehydrogenase 1 mutation Y208C attenuates dimerization ability.

Shota Kawakami, Masaki Michishita, Motoharu Sakaue, Masami Morimatsu, Mitsuki Uemura, Nobuaki Kashiwagi, Marika Maeda, Yukino Machida, Daigo Azakami, Ai S Egusa and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncology letters, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Shota KawakamiSchool of Veterinary Nursing and Technology, Faculty of Veterinary Science, Musashino, Tokyo 180-8602, Japan.
Masaki MichishitaLaboratory of Veterinary Pathology, School of Veterinary Science, Musashino, Tokyo 180-8602, Japan.
Motoharu SakaueLaboratory of Anatomy II, Department of Veterinary Medicine, School of Veterinary Medicine, Azabu University, Sagamihara, Kanagawa 252-5201, Japan.
Masami MorimatsuLaboratory of Animal Science and Medicine, Department of Disease Control, Graduate School of Veterinary Medicine, Hokkaido University, Sapporo 060-0818, Japan.
Mitsuki UemuraSchool of Veterinary Nursing and Technology, Faculty of Veterinary Science, Musashino, Tokyo 180-8602, Japan.
Nobuaki KashiwagiSchool of Veterinary Nursing and Technology, Faculty of Veterinary Science, Musashino, Tokyo 180-8602, Japan.
Marika MaedaLaboratory of Veterinary Hygiene, School of Veterinary Science, Nippon Veterinary and Life Science University, Musashino, Tokyo 180-8602, Japan.
Yukino MachidaLaboratory of Veterinary Pathology, School of Veterinary Science, Musashino, Tokyo 180-8602, Japan.
Daigo AzakamiLaboratory of Clinical Oncology, Cooperative Department of Veterinary Medicine, Faculty of Agriculture, Tokyo University of Agriculture and Technology, Fuchu, Tokyo 183-8538, Japan.
Ai S EgusaDepartment of Applied Life Science, Faculty of Food Science, Nippon Veterinary and Life Science University, Musashino, Tokyo 180-8602, Japan.
Eri OnozawaSchool of Veterinary Nursing and Technology, Faculty of Veterinary Science, Musashino, Tokyo 180-8602, Japan.
Katsumi IshiokaSchool of Veterinary Nursing and Technology, Faculty of Veterinary Science, Musashino, Tokyo 180-8602, Japan.
Masami WatanabeDepartment of Urology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Okayama 700-8558, Japan.
Yoshikazu TanakaResearch Center for Animal Life Science, Nippon Veterinary and Life Science University, Musashino, Tokyo 180-8602, Japan.
Toshinori OmiSchool of Veterinary Nursing and Technology, Faculty of Veterinary Science, Musashino, Tokyo 180-8602, Japan.
Kazuhiko OchiaiSchool of Veterinary Nursing and Technology, Faculty of Veterinary Science, Musashino, Tokyo 180-8602, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Isocitrate dehydrogenase 1 (IDH1) mutations are common in gliomas, acute myeloid leukemia, and chondrosarcoma. The mutation 'hotspot' is a single arginine residue, R132. The R132H mutant of IDH1 produces the 2-hydroxyglutarate (2-HG) carcinogen from α-ketoglutarate (α-KG). The reduction of α-KG induces the accumulation of hypoxia-inducible factor-1α subunit (HIF-1α) in the cytosol, which is a predisposing factor for carcinogenesis. R132H is the most common IDH1 mutation in humans, but mutations at the R132 residue can also occur in tumor tissues of dogs. The current study reported the discovery of a novel Tyr208Cys (Y208C) mutation in canine IDH1 (cIDH1), which was isolated from 2 of 45 canine chondrosarcoma cases. As the genomic DNA isolated from chondrosarcoma tissue was mutated, but that isolated from blood was not, Y208C mutations were considered to be spontaneous somatic mutations. The isocitrate dehydrogenase activity of the Y208C mutant was attenuated compared with that of wild-type (WT) cIDH1, but the attenuation of Y208C was less intense than that of the R132H mutation. The induction of HIF-1α response element activity and cell retention of HIF-1α were not increased by Y208C overexpression.

Indexed as

caninechondrosarcomadimerizationgliomaisocitrate dehydrogenase 1mutation

Identifiers

PMID33123262
PMCPMC7586285

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.